로딩 중…
지수 로딩 중…
Aptamer Sciences Inc.
291650· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩820+2.24%
2026-06-19
Price Chart
Aptamer Sciences Inc.-28.07%
Financials
Investment Metrics(as of 2026-06-19)
| Metric | Value |
|---|---|
| Size | |
| Market Cap | 50.05B KRW |
| Revenue | 3.62B KRW |
| Net Income | -3.19B KRW |
| Total Assets | 45.93B KRW |
| Net Assets | 26.74B KRW |
| Employees | 55 |
| Value | |
| P/B | 1.87x |
| P/S | 13.83x |
| FCF Yield | -19.36% |
| Profitability | |
| ROE | -11.93% |
| ROA | -6.95% |
| Op. Margin | -215.62% |
| Revenue Growth | 19.02% |
| Financial Health | |
| Debt Ratio | 71.75% |
| Total Debt | 11.83B KRW |
| FCF | -9.69B KRW |
| Cash | 18.90B KRW |
| Current Ratio | 1.65x |
| Performance | |
| 1Y Return | -28.07% |
| 1M Return | -30.21% |
| From 52W High | -58.96% |
| 1Y MDD | -58.68% |
| Trading | |
| Volume | 271,586 shares |
| Foreign Own. | 2.06% |
| Per Share | |
| EPS | -252 KRW |
| BPS | 649 KRW |
Company Info
Aptamer Sciences, established in 2011 as a POSTECH spin-off, listed on KOSDAQ in 2020 and expanded into the Contract Research Organization (CRO) business by acquiring ISS in 2024. The company is developing solid and blood cancer therapeutics leveraging its aptamer technology platform, with its flagship product, Aptodetect Lung, being an excellent in-vitro diagnostic kit. Aptamer Sciences is further building expertise in biopharmaceutical analysis and establishing a comprehensive new drug development system to advance next-generation anticancer drug development.